{"task_id": "bcafaf6f5edf1e74", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 186/464)", "text": "multisystem\ninvolvement\n174\nNon-Hodgkin\u2019s Lymphoma\n\n--- Page 196 ---\nSTAGING\nTUMOR BURDEN\na combination of stage, bulki\nness (>10 cm in greatest diameter), B symptoms\nANN ARBOR STAGE\n\u0002\nI\nSingle node region\n\u0002\nII\nTwo or more node regions on same side of\ndiaphragm\n\u0002\nIII\nInvolvement on both sides of diaphragm\n\u0002\nIV\nDiffuse or disseminated foci of involvement\nof one or more extralymphatic sites (e.g.\nbone marrow, extranodal sites that cannot\nbe included in one radiation field)\nDESIGNATIONS\n\u0002 E\nsingle extralymphatic site (i.e. involvement\noutside of lymph nodes, spleen, thymus, and Wal\ndeyer\u2019s ring) or involvement by direct extension\n\u0002 S\nsplenic involvement\n\u0002 A\nno B symptoms\n\u0002 B\nweight loss >10% over 6 months, fever >388C\n[100.48F], drenching night sweats\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, peripheral smear, lytes, urea, Cr,\nAST, ALT, ALP, bilirubin, Ca, PO4, Mg, uric acid,\nLDH, albumin, quantitative immunoglobulin,\nserum protein electrophoresis, HBV, HCV, and\nHIV serology\n\u0002\nIMAGING\nCXR, CT chest/abdomen/pelvis, PET\nscan\n\u0002\nLYMPH NODE BIOPSY\n\u0002\nBONE MARROW BIOPSY WITH SURFACE MARKERS\nSPECIAL\n\u0002 MRI SPINE\nif suspect spinal cord compression\n\u0002 MUGA SCAN\nevaluate cardiac function prior to\nanthracycline therapy for patients with signifi\ncant cardiac risk factors\nDIAGNOSTIC AND PROGNOSTIC ISSUES\nIMMUNOPHENOTYPE OF SELECTED\nLYMPHOMAS\nCLL\nMCL\nFL\nMZL\nCD20\n+\n+\n+\n+\nCD5\n+\n+\nCD23\n+\nCD43\n+\n+\n+\nCD10\n+\nINTERNATIONAL PROGNOSTIC INDEX (IPI)\n\u0002\nFACTORS\nage >60, serum LDH >normal, ECOG\nperformance status \u00062, Ann Arbor clinical stage\nIII or IV, extranodal disease sites \u00062 (defined as\ninvolvement of organs other than lymph nodes,\nspleen, thymus, and Waldeyer\u2019s ring)\nDIAGNOSTIC AND PROGNOSTIC ISSUES (CONT\u2019D)\n\u0002\nSCORING\n1 point per factor, with a score of 0 5\n\u0002\nUTILITY\n5 year overall survival approximately\n73%, 51%, 43%, and 26% for IPI of 0 1, 2, 3, and\n4 5. With the new revised IPI (post rituximab era),\n5 year overall survival 94%, 79%, and 55% for IPI of\n0, 1 2, and 3 5, respectively\nFOLLICULAR LYMPHOMA INTERNATIONAL\nPROGNOSTIC INDEX (FLIPI)\n\u0002\nFACTORS\nage >60, serum LDH >normal, hemo\nglobin <120 g/L [ <12 g/dL], Ann Arbor clinical\nstage III or IV, involved nodal sites >4\n\u0002\nSCORING\n1 point per factor, with a score of 0 5\n\u0002\nUTILITY\nfor follicular lymphoma patients specifi\ncally; 5 year survival approximately 91%, 78%, and\n52% for FLIPI of 0 1, 2 and 3 5, respectively\nMANAGEMENT\nINDOLENT LYMPHOMAS\n\u0002\nLIMITED STAGE (IA or IIA, 10%)\nradiation (10 year\nsurvival 50%)\n\u0002\nADVANCED STAGE (IB, IIB, III, IV, or any bulky disease,\n90%)\nif asymptomatic (40%), watchful waiting. If\nsymptomatic or threatening disease (60%), CVPR\n\u00038 cycles (cyclophosphamide, vincristine, predni\nsone, and rituximab), followed by maintenance\nrituximab for 2 years if PR/CR (15% relapse with\nmaintenance rituximab compared to 35% for CVPR\nalone or 70% for CVP alone). Second line agents\ninclude fludarabine, cyclophosphamide, rituximab,\nI131 tositumomab, and Y90 ibritumomab. Stem cell\ntransplant in fit individuals\nAGGRESSIVE LYMPHOMAS\n\u0002\nLIMITED STAGE (IA or IIA, 30%)\nCHOPR (cyclopho\nsphamide, doxorubicin, vincristine, prednisone,\nrituximab) \u00033 cycles. PET scan afterwards, if com\nplete remission, one more cycle; otherwise, give\ninvolved field radiation\n\u0002\nADVANCED STAGE (IB, IIB, III, IV, or any bulky disease,\n70%)\nCHOPR \u00036. PET scan afterwards, if local\nresidual disease, give involved field radiation; if\ndiffuse residual disease, consider salvage therapy\n(see below). For patients with bone marrow/per\nipheral blood involvement,\nintrathecal che\nmotherapy may be considered as 5 20% chance\nof leptomeningeal disease otherwise\n\u0002\nSALVAGE\nGDPR (gemcitabine, dexamethasone,\ncisplatin, rituximab) or RICE (rituximab, ifosfamide,\ncarboplatin, etoposide), followed by autologous\nstem cell transplant\nHIGHLY AGGRESSIVE LYMPHOMAS\n\u0002 BURKITT\u2019S LYMPHOMA\nexpedited staging (within\n1 2 days). For low risk disease (stage I or II, non\nbulky\n<5 cm, no bone marrow/blood/CNS\nNon-Hodgkin\u2019s Lymphoma\n175", "text_length": 3967, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 186/464)", "type": "chunk", "chunk_index": 185, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.501551", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.502431", "status": "complete", "chunks_added": 3}